ETX0462

ETX0462

Identifiers
IUPAC name [(1R,7S)-7-(N-hydroxy-N'-methylcarbamimidoyl)-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate
PubChem CID	135376294
ChemSpider	131615996
Chemical and physical data
Formula	C10H14N6O6S
Molar mass	346.32 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN=C([C@@H]1C2=C(C=NN2C)[C@@H]3CN1C(=O)N3OS(=O)(=O)O)NO
InChI InChI=1S/C10H14N6O6S/c1-11-9(13-18)8-7-5(3-12-14(7)2)6-4-15(8)10(17)16(6)22-23(19,20)21/h3,6,8,18H,4H2,1-2H3,(H,11,13)(H,19,20,21)/t6-,8-/m0/s1 Key:HXTQIYBHDSBEJG-XPUUQOCRSA-N

ETX0462 is an experimental antibiotic drug which acts both as a β-lactamase inhibitor and also has separate antibiotic activity in its own right. It is active against a range of drug-resistant bacteria of concern including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. While ETX0462 is still in pre-clinical research and has not yet reached clinical trials, it was hailed as a significant advance as it represents an example of a completely new structural class of antibiotics, so even if this particular molecule does not get developed for medical use it is likely that related compounds will continue to be developed.

See also

• Avibactam
• Durlobactam
• Diazabicyclooctane β-lactamase inhibitor